Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium

被引:6
|
作者
Krzywdzinska, Agnieszka [1 ]
Pula, Bartosz [2 ]
Czyz, Anna [3 ]
Krzymieniewska, Beata [1 ]
Kiernicka-Parulska, Jolanta [4 ]
Mierzwa, Anna [4 ]
Szymczak, Donata [5 ]
Milanowska, Aneta [5 ]
Kiraga, Aleksandra [5 ]
Kwiecien, Iwona [6 ]
Zaleska, Joanna [7 ]
Jamroziak, Krzysztof [8 ]
机构
[1] Inst Hematol & Transfus Med, Lab Immunophenotyping, PL-02776 Warsaw, Poland
[2] Inst Hematol & Transfus Med, Dept Hematol, PL-02776 Warsaw, Poland
[3] Wroclaw Med Univ, Dept Hematol & Bone Marrow Transplantat, PL-50367 Wroclaw, Poland
[4] Univ Hosp Lords Transfigurat, Dept Haematol & Bone Marrow Transplantat, Flow Cytometry Lab, Haematol Clin Lab, PL-60101 Poznan, Poland
[5] Univ Hosp Wroclaw, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Flow Cytometry & Cytomorphol Lab, PL-50367 Wroclaw, Poland
[6] Mil Inst Med, Dept Internal Med & Hematol, Lab Hematol & Flow Cytometry, PL-04141 Warsaw, Poland
[7] Med Univ Lublin, Dept Expt Hematooncol, PL-20059 Lublin, Poland
[8] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
关键词
multiple myeloma; minimal residual disease; flow cytometry; CONSENSUS GUIDELINES; DARATUMUMAB THERAPY; SURVIVAL OUTCOMES; MRD DETECTION; PLASMA-CELLS; SINGLE-TUBE; STANDARDIZATION; CD38;
D O I
10.3390/diagnostics11101872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials. Here, we report the results of the first study evaluating the reproducibility of high-sensitivity flow cytometry MM MRD assessment in four laboratories in Poland. EuroFlow protocols for instrument setting standardization and sample preparation in MM MRD assessment were implemented in each laboratory. In the inter-laboratory reproducibility study, 12 bone marrow samples from MM patients were distributed and processed in participant laboratories. In the inter-operator concordance study, 13 raw data files from MM MRD measurements were analyzed by five independent operators. The inter-laboratory study showed high 95% overall concordance of results among laboratories. In the inter-operator study, 89% of MRD results reported were concordant, and the highest immunophenotype interpretation differences with regard to expression of CD27, CD45, CD81 were noticed. We confirmed the applicability and feasibility of the EuroFlow protocol as a highly sensitive method of MRD evaluation in MM. Results of our inter-center comparison study demonstrate that the standardization of MM MRD assessment protocols is highly desirable to improve quality and comparability of results within and between different clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Kumar, Shaji
    Paiva, Bruno
    Anderson, Kenneth C.
    Durie, Brian
    Landgren, Ola
    Moreau, Philippe
    Munshi, Nikhil
    Lonial, Sagar
    Blade, Joan
    Mateos, Maria-Victoria
    Dimopoulos, Meletios
    Kastritis, Efstathios
    Boccadoro, Mario
    Orlowski, Robert
    Goldschmidt, Hartmut
    Spencer, Andrew
    Hou, Jian
    Chng, Wee Joo
    Usmani, Saad Z.
    Zamagni, Elena
    Shimizu, Kazuyuki
    Jagannath, Sundar
    Johnsen, Hans E.
    Terpos, Evangelos
    Reiman, Anthony
    Kyle, Robert A.
    Sonneveld, Pieter
    Richardson, Paul G.
    McCarthy, Philip
    Ludwig, Heinz
    Chen, Wenming
    Cavo, Michele
    Harousseau, Jean-Luc
    Lentzsch, Suzanne
    Hillengass, Jens
    Palumbo, Antonio
    Orfao, Alberto
    Rajkumar, S. Vincent
    Miguel, Jesus San
    Avet-Loiseau, Herve
    LANCET ONCOLOGY, 2016, 17 (08): : E328 - E346
  • [32] Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal, Mikhail
    SEMINARS IN HEMATOLOGY, 2018, 55 (01) : 4 - 12
  • [33] Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice
    Owen, RG
    Rawstron, AC
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) : 732 - 733
  • [34] Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma
    Gormley, Nicole J.
    Turley, Danielle M.
    Dickey, Jennifer S.
    Farrell, Ann T.
    Reaman, Gregory H.
    Stafford, Elizabeth
    Carrington, Lea
    Marti, Gerald E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) : 73 - 80
  • [35] Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
    Flanders, Aaron
    Stetler-Stevenson, Maryalice
    Landgren, Ola
    BLOOD, 2013, 122 (06) : 1088 - 1089
  • [36] MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA USING POLYCHROMATIC FLOW CYTOMETRY
    Rihova, Lucie
    Varmuzova, Tamara
    Zarbochova, Pavla
    Suska, Renata
    Penka, Miroslav
    Hajek, Roman
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (06) : 404 - 405
  • [37] Minimal residual disease in multiple myeloma: current status
    Ding, Hong
    Xu, Juan
    Lin, Zhimei
    Huang, Jingcao
    Wang, Fangfang
    Yang, Yan
    Cui, Yushan
    Luo, Hongmei
    Gao, Yuhan
    Zhai, Xinyu
    Pang, Weicui
    Zhang, Li
    Zheng, Yuhuan
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [38] MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: IMAGING TECHNIQUES
    Zamagni, E.
    Tacchetti, P.
    Pantani, L.
    Mancuso, K.
    Zannetti, B.
    Rocchi, S.
    Rizzello, I
    Caratozzolo, I
    Nanni, C.
    Fanti, S.
    Cavo, M.
    HAEMATOLOGICA, 2018, 103 : 1 - 2
  • [39] Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma
    Bhutani M.
    Usmani S.Z.
    Taneja A.
    Landgren O.
    Current Radiology Reports, 4 (12)
  • [40] Minimal residual disease diagnostics in patients with multiple myeloma
    Huhn, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 128 - 128